近年來(lái)兒童癌癥的治療取得了長(zhǎng)足進(jìn)步,，但依然存在很多兒童腫瘤類型無(wú)法醫(yī)治,。在線發(fā)表于愛(ài)思唯爾期刊《癌癥治療評(píng)論》（Cancer Treatment Reviews）的一篇文章，報(bào)道了以組織缺氧作為藥物標(biāo)靶治療兒童癌癥的新方法,。
目前,，人們普遍認(rèn)為腫瘤部位組織缺氧是導(dǎo)致治療失敗和多種成人惡性腫瘤的罪魁禍?zhǔn)住＝M織缺氧被認(rèn)為抵制了放射療法和化療,，導(dǎo)致腫瘤細(xì)胞內(nèi)部的適應(yīng)性變化,，由此引起新的血管發(fā)生和程序性細(xì)胞死亡。
組織缺氧有很多的不良影響,，但科學(xué)家同時(shí)還發(fā)現(xiàn),，如果能夠以組織缺氧為藥物標(biāo)靶，那么戰(zhàn)勝癌癥的希望就大大增加了。缺氧誘導(dǎo)因子1（HIF-1）是最具吸引力的藥物標(biāo)靶,，而且HIF-1抑制劑已經(jīng)顯示出了一些治療效果,。研究人員認(rèn)為，如果能夠研究出專門(mén)攻擊這種腫瘤的藥物,，兒童惡性腫瘤的治療將取得更大的進(jìn)步,。
該文章表明，組織缺氧為腫瘤治療提供了一種潛在的治療靶標(biāo),，這將有助于徹底攻克兒童癌癥,。（科學(xué)網(wǎng) 荔濤/編譯）
生物谷推薦原始出處：
（Cancer Treatment Reviews），doi:10.1016/j.ctrv.2007.11.005,，J.K. Adamski, G.W.J. Makin
The cellular adaptations to hypoxia as novel therapeutic targets in childhood cancer
J.K. Adamskia, E.J. Estlinb, and G.W.J. Makin
Summary
Exposure of tumour cells to reduced levels of oxygen (hypoxia) is a common finding in adult tumours. Hypoxia induces a myriad of adaptive changes within tumour cells which result in increased anaerobic glycolysis, new blood vessel formation, genetic instability and a decreased responsiveness to both radio and chemotherapy. Hypoxia correlates with disease stage and outcome in adult epithelial tumours and increasingly it is becoming apparent that hypoxia is also important in paediatric tumours. Despite its adverse effects upon tumour response to treatment hypoxia offers several avenues for new drug development. Bioreductive agents already exist, which are preferentially activated in areas of hypoxia, and thus have less toxicity for normal tissue. Additionally the adaptive cellular response to hypoxia offers several novel targets, including vascular endothelial growth factor (VEGF), carbonic anhydrase, and the central regulator of the cellular response to hypoxia, hypoxia inducible factor-1 (HIF-1). Novel agents have emerged against all of these targets and are at various stages of clinical and pre-clinical development. Hypoxia offers an exciting opportunity for new drug development that can include paediatric tumours at an early stage.
